ASPIRED

Multi-centre open label randomised controlled trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in acute unexplained syncope patients

BHF (CS/F/20/190016); £1,303,649 over 4 years
Lay summary:
Diagnosing underlying dysrhythmia in people presenting to the emergency department is difficult. There is evidence that the diagnostic yield for detecting underlying dysrhythmia is highest when cardiac monitoring devices are applied early in patients with acute unexplained syncope, ideally at the index visit.
The ASPIRED study is a UK open label, prospective parallel group multicentre randomised controlled trial of an immediate 14-day ambulatory patch heart monitor versus standard care (Holter/extended ambulatory monitor as per NICE guidance) in over 2,000 people presenting acutely with unexplained syncope to over 30 UK hospitals.
The primary endpoint will be the number of episodes of syncope at one year. Secondary end points include cost effectiveness, the number of episodes of syncope at 90 days and 2 years, clinically significant cardiac dysrhythmia, all cause death and quality of life.

Recruitment commenced July 2022 and will take place over 18 months.

Brief 2 page summary for potential sites

ASPIRED protocol v3.0

ASPIRED PIS/Consent v3.0

Site recruitment video – all you need to know

More detailed slideset about study

ECTU website

Please contact us via email: mattreed@ed.ac.uk or aspired.study@ed.ac.uk ;or via twitter @theaspiredstudy if you are interested in being a recruiting site.

Status: active

Start Date

August 2022

Chief Investigator

Professor Matt Reed

Coordinated by

Nicola Freeman

Main Trial Site

Royal Infirmary of Edinburgh, St John's Hospital and the Western General Hospital

End date

July 2026